Shengxiang Biotech announced that the company's human OTX1/MTHFD2/FAR1 gene methylation test kit recently obtained a medical device registration certificate issued by the State Drug Administration. The registration category is a domestic Class III in vitro diagnostic reagent, which is valid until November 9, 2031. This product is used to qualitatively detect the methylation status of OTX1, MTHFD2, and FAR1 genes in human peripheral blood plasma in vitro, and provides a molecular reference basis for auxiliary diagnosis of people at high risk of primary hepatocellular carcinoma. Product sales and profit contributions are affected by factors such as market expansion, overall brand influence, and actual market demand, and are uncertain.

Shengxiang Biotech announced that the company's human OTX1/MTHFD2/FAR1 gene methylation test kit recently obtained a medical device registration certificate issued by the State Drug Administration. The registration category is a domestic Class III in vitro diagnostic reagent, which is valid until November 9, 2031. This product is used to qualitatively detect the methylation status of OTX1, MTHFD2, and FAR1 genes in human peripheral blood plasma in vitro, and provides a molecular reference basis for auxiliary diagnosis of people at high risk of primary hepatocellular carcinoma. Product sales and profit contributions are affected by factors such as market expansion, overall brand influence, and actual market demand, and are uncertain.